期刊文献+

瑞舒伐他汀联合硝苯地平的降压作用及其对血管内皮功能的影响

Synergic Hypotensive Effects of Rosuvastatin and Nifedipine Controlled Released Tablet and Their Influence on Vascular Endothelial Function
下载PDF
导出
摘要 目的评价硝苯地平控释片联用瑞舒伐他汀对1级、2级原发性高血压患者血压及血管内皮功能的影响。方法采用随机单盲法将114例患者分为两组,对照组58例给予硝苯地平控释片30 mg、每日1次,联用组加用瑞舒伐他汀片10 mg、每日1次。另以50例正常血压者为正常组。12周后观察3组血压及血浆内皮素-1(ET-1)、一氧化氮(NO)水平的变化。结果两组患者的收缩压和舒张压均显著降低,但联用组较对照组血压下降更显著。联用组血浆ET-1水平治疗后较治疗前降低40.5%(P<0.01),较对照组治疗后降低28.6%(P<0.05);NO水平较治疗前升高81.0%(P<0.01),较对照组治疗后升高57.7%(P<0.01)。结论瑞舒伐他汀与硝苯地平控释片联用有明显的协同降压作用,并伴有血管内皮功能的改善,这可能是他汀类药物发挥协同降压作用的机制之一。 Objective To evaluate the effects of the combination of rosuvastatin and Nifedipine Controlled Released Tablet on the blood pressure and the vascular endothelial function in grade 1-2 essential hypertension. Methods By using the randomized, Single-blind, controlled method, 114 patients with essential hypertension were divided into two groups. The control group(58 cases) was given Nifedip-ine Controlled Released Tablet 30 mg, once daily, while the combination group(56 cases) was given Nifedipine Controlled Released Tablet 30 mg, once daily, and Rosuvastatin Tablet 10mg, once daily. Other 50 cases of normal blood pressure were taken as the control group. After 12 weeks, the changes of blood pressure, plasma endothelin-l(ET-1) and nitric oxide(NO) levels were observed in 3 groups. Results The systolic and diastolic blood pressures were significantly decreased in both groups, but the combination group was decreased more significantly than the control group. The plasma ET-1 level after treatment in the combinantion group was decreased by 40. 5% compared before treatment( P 〈 0. 01) and by 28.6% compared with the control group( P 〈 0. 05); the NO level after treatment in the combination group was increased by 81.0% compared with before treatment and increased by 57.7% compared with the control group (P 〈 0. 01 ). Conclusion The combination of rosuvastatin and Nifedipine Controlled Released Tablet has significant synergic hy-potensive effect complicating the improvement of vascular endothelial function, which may be one of mechanisms of statins drugs respon-sible for the synergic hypotensive effect.
出处 《中国药业》 CAS 2013年第15期38-40,共3页 China Pharmaceuticals
关键词 原发性高血压 瑞舒伐他汀 硝苯地平控释片 血管内皮 内皮素-1 一氧化氮 essential hypertension rosuvastatin Nifedipine Controlled Released Tablet vascular endothelial endothelin - 1 nitric oxide
  • 相关文献

参考文献10

  • 1周静波.他汀类药物多效性对心肌的保护作用进展[J].中国药业,2011,20(12):78-79. 被引量:1
  • 2Liao J, Farmer JA. Statins as adjunctive therapy in the management of hy- pertension [ J ]. Curr Atheroseler Rep, 2010,12 (5) : 349 - 354.
  • 3Kostapanos MS, Milionis HJ, Elisaf MS. Current role of statins in the treat- ment of essential hypertension[J]. Expert Opin Pharmacother, 2010, 11(16): 2 635 -2 650.
  • 4匡永东,吕良东,龚明.瑞舒伐他汀对高血压合并高脂血症患者血压的影响[J].中国药业,2012,21(7):47-48. 被引量:7
  • 5Di Napoli P, Taccardi AA, Grilli A, et al. Chronic treatment with rosuvas- tatin modulates nitric oxide synthase expression and reduces ischemia- repeffusion injury in rat hearts[./]. Cardiovasc Res, 2005,66(3): 462- 471.
  • 6Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide [ J ]. Circ Res, 2005,97(12): 1 232 - 1235.
  • 7Sarkar K, Sinha AK, Mehta JL. The role of statins in endothelial dysfunction in hypertension [ J ]. Curr Opin Cardiol, 2006,21 (4) : 316 - 321.
  • 8汪保孝,张宴斌,吴建军.阿托伐他汀对急性脑梗死患者超敏C-反应蛋白和血脂的影响[J].中国药业,2012,21(5):10-11. 被引量:14
  • 9Rev Med Liege. First evidence of greater cardiovascular protective effects of newer as compared to old antihypertensive drugs treatments: the ASCOT - BPLA results [ J ]. Krzesinski JM, 2005,60 (10) : 820 - 826.
  • 10Feldstein CA. Statins in hypertension: are they a new class of antihyper- tensive agents [ J ]. Am J Ther, 2010,17 ( 3 ) : 255 - 262.

二级参考文献24

  • 1李建军.高血压可能是一种炎症相关性疾病[J].高血压杂志,2005,13(9):526-527. 被引量:46
  • 2曹红,孙长凯,许晶,陶定波,王喜宽,汪秋艳,侯宇.他汀类药物对脑梗死患者血清C反应蛋白及预后的影响[J].中华急诊医学杂志,2006,15(2):160-163. 被引量:17
  • 3Adam O,Neuberger HR,Bohm M.Prevention of atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme A roduc-tase inhibitors[J].Circulation,2008,118(12):1 285-1 293.
  • 4Ramasubbu K,Estep J,White DL,et al.Experimental and clinical basis for the use of statins in patients with is chemic and nonis chemic cardiomyopatby[J].Am J coll Cardiol,2008,51 (4):415-426.
  • 5Habibi J,Whaley-Cennell A,Qezi MA,et al.Rosuvastatin,a 3-hydroxyl-3-metbylglutaryl cocnzyme A roductase inhibitor,decreases cardiac oxidative stress and remodeling in Ben2 transgenic rats[J].Endocrinology,2007,148(5):2 181-2 188.
  • 6Reiss AB,Wirkowski E.Roie of HMG-CoA reductase inhibitors in neurological disorders:progress to dete[J].Drugs,2007,67 (15):2 111-2 120.
  • 7Undas A,Brummel KE,Musial J,et al.Simvastotin depresses blood clotting by inhibiting activation of prothrombin,factor V,and factorx Ⅲ and by enhancing factor Vainactivation[J].Circulation,2001,103:2 248-2 253.
  • 8Gruaszi M,Belletti S,Lenatti L,et al.Effects of cardioversion of atrial fibrillation on endothelial function in hypertension or diabetes[J].Eur J Clin Invest,2007,37(1):26-34.
  • 9Goldberger JJ,Subacius H,Schaechter A,et al.Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy[J].J Am Coll Cardiol,2006,48(6):1 228-1 233.
  • 10Adam O,Frost G,Custodis F,et al.Role of RacI GTPase activation in atrial fibrillation[J].J Am Coil Cardiol,2007,50(4):359-367.

共引文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部